Literature DB >> 15607732

Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor.

Takatoshi Soga1, Takahide Ohishi, Tetsuo Matsui, Tetsu Saito, Mitsuyuki Matsumoto, Jun Takasaki, Shun-Ichiro Matsumoto, Masazumi Kamohara, Hideki Hiyama, Shigeru Yoshida, Kazuhiro Momose, Yoshitaka Ueda, Hitoshi Matsushime, Masato Kobori, Kiyoshi Furuichi.   

Abstract

A lysophospholipid series, such as lysophosphatidic acid, lysophosphatidylserine, and lysophosphatidylcholine (LPC), is a bioactive lipid mediator with diverse physiological and pathological functions. LPC has been reported to induce insulin secretion from pancreatic beta-cells, however, the precise mechanism has remained elusive to date. Here we show that an orphan G-protein-coupled receptor GPR119 plays a pivotal role in this event. LPC potently enhances insulin secretion in response to high concentrations of glucose in the perfused rat pancreas via stimulation of adenylate cyclase, and dose-dependently induces intracellular cAMP accumulation and insulin secretion in a mouse pancreatic beta-cell line, NIT-1 cells. The Gs-protein-coupled receptor for LPC was identified as GPR119, which is predominantly expressed in the pancreas. GPR119-specific siRNA significantly blocked LPC-induced insulin secretion from NIT-1 cells. Our findings suggest that GPR119, which is a novel endogenous receptor for LPC, is involved in insulin secretion from beta-cells, and is a potential target for anti-diabetic drug development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607732     DOI: 10.1016/j.bbrc.2004.11.120

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  103 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

Authors:  Ping Liu; Zhiyong Hu; Byron G DuBois; Christopher R Moyes; David N Hunter; Cheng Zhu; Nam Fung Kar; Yuping Zhu; Joie Garfunkle; Ling Kang; Gary Chicchi; Anka Ehrhardt; Andrea Woods; Toru Seo; Morgan Woods; Margaret van Heek; Karen H Dingley; Jianmei Pang; Gino M Salituro; Joyce Powell; Jenna L Terebetski; Viktor Hornak; Louis-Charles Campeau; Joe Lamberson; Fez Ujjainwalla; Michael Miller; Andrew Stamford; Harold B Wood; Timothy Kowalski; Ravi P Nargund; Scott D Edmondson
Journal:  ACS Med Chem Lett       Date:  2015-07-10       Impact factor: 4.345

Review 3.  G protein-coupled receptors as targets for anti-diabetic therapeutics.

Authors:  Da Young Oh; Jerrold M Olefsky
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

4.  Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.

Authors:  Shu-yong Zhang; Jing Li; Xin Xie
Journal:  Acta Pharmacol Sin       Date:  2014-03-31       Impact factor: 6.150

5.  Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock.

Authors:  Oliver Murch; Marika Collin; Bruno Sepodes; Simon J Foster; Helder Mota-Filipe; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

6.  G protein-coupled receptors and insulin secretion: 119 and counting.

Authors:  S R Murthy Madiraju; Vincent Poitout
Journal:  Endocrinology       Date:  2007-06       Impact factor: 4.736

Review 7.  Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects.

Authors:  Stefano Costanzi; Susanne Neumann; Marvin C Gershengorn
Journal:  J Biol Chem       Date:  2008-04-02       Impact factor: 5.157

8.  Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.

Authors:  Alexandra Feldman; Sebastian K Eder; Thomas K Felder; Lyudmyla Kedenko; Bernhard Paulweber; Andreas Stadlmayr; Ursula Huber-Schönauer; David Niederseer; Felix Stickel; Simon Auer; Elisabeth Haschke-Becher; Wolfgang Patsch; Christian Datz; Elmar Aigner
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

9.  N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.

Authors:  Zhi-Liang Chu; Chris Carroll; Ruoping Chen; Jean Alfonso; Veronica Gutierrez; Hongmei He; Annette Lucman; Charles Xing; Kristen Sebring; Jinyao Zhou; Brandee Wagner; David Unett; Robert M Jones; Dominic P Behan; James Leonard
Journal:  Mol Endocrinol       Date:  2009-11-09

Review 10.  Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient.

Authors:  Charmaine D Rochester; Oluwaranti Akiyode
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.